

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Jubilant DraxImage Inc. d/b/a Jubilant Radiopharma 2. 790 Township Line Rd. Ste. 325 Yardley, PA 19067		In accordance with letter dated August 15, 2022,	4. Expiration Date: July 31, 2025
		3. License No.: 09-32781-03MD is amended in its entirety to read as follows:	5. Docket No.: 030-38279 Reference No.: 030-30262/24-04206-11MD
6. Byproduct, source, and/or special nuclear material A. Any byproduct material with Atomic Numbers 1 through 83 with Exceptions B. Molybdenum-99 C. Technetium-99m D. Iodine-131	7. Chemical and/or physical form A. Any B. Any C. Any D. Any	8. Maximum amount that licensee may possess at any one time under this license A. 500 millicuries per radionuclide and 1 curie total B. 200 curies total C. 200 curies total D. 900 millicuries total	9. Authorized use A. For preparation and distribution of radioactive drugs, including compounding of iodine-131 and radiochemicals for medical use in accordance with 10 CFR 32.72 and for non-medical use to authorized recipients. For redistribution of unused molybdenum-99/technetium-99m and strontium-82/rubidium-82 generators to authorized recipients for medical use, in accordance with 10 CFR 32.72, and for non-medical use to authorized recipients. B. Same as Subitem No. 9.A. C. Same as Subitem No. 9.A. D. Same as Subitem No. 9.A.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License No.:
09-32781-03MD

Amendment No. 20


Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Xenon-133	E. Any	E. 2 curies total	E. Same as Subitem No. 9.A.
F. Thallium-201	F. Any	F. 1 curie total	F. Same as Subitem No. 9.A.
G. Indium-111	G. Any	G. 250 millicuries total	G. Same as Subitem No. 9.A.
H. Gallium-67	H. Any	H. 250 millicuries total	H. Same as Subitem No. 9.A.
I. Iodine-123	I. Any	I. 250 millicuries total	I. Same as Subitem No. 9.A.
J. Any byproduct material permitted by 10 CFR 31.11	J. Prepackaged Kits	J. 20 millicuries total	J. For redistribution to specific licensees or general licensees, pursuant to 10 CFR 31.11, provided the packaging and labeling remain unchanged.
K. Any byproduct material permitted by 10 CFR 35.65	K. Sealed Sources	K. 300 millicuries total	K. For redistribution of sealed sources initially distributed by a manufacturer licensed in accordance with 10 CFR 32.74, to specifically authorized recipients for medical use. In accordance with 10 CFR 32.74, the licensee is authorized to distribute sources to persons licensed pursuant to 10 CFR 35.65(a), or under equivalent licenses of any Agreement State.
L. Yttrium-90	L. Any	L. 1 curie total	L. Same as Subitem No. 9.A.
M. Uranium- depleted in Uranium-235	M. Metal	M. 200 kilograms total	M. For shielding for molybdenum-99/ technetium-99m generators.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
09-32781-03MD

Amendment No. 20

Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

- | | | | |
|---|---|--|--|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| N. Yttrium-90 permitted by 10 CFR 35.1000 | N. Microspheres (Sirtex Medical, Model SIR-Spheres) | N. 1 curie total | N. For preparation and redistribution of microspheres that have been registered either with NRC under 10 CFR 32.210 or with an Agreement State and have been distributed in accordance with an NRC or Agreement State specific license authorizing distribution to persons specifically authorized by an NRC or Agreement State license to receive, possess and use the microspheres for medical use as permitted by 10 CFR 35.1000. |
| O. Strontium-82 | O. Any | O. 1.5 curies total | O. Same as Subitem No. 9.A. |
| P. Rubidium-82 | P. Any | P. 1.5 curies total | P. Same as Subitem No. 9.A. |
| Q. Strontium-85 | Q. Any | Q. 1.5 curies total | Q. For possession and storage incident to redistribution of Jubilant DraxImage Inc. Model RUBY-FILL Rubidium Rb 82 generators. |
- 

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 2795 Universal Drive, Saginaw, Michigan, 48603.

11. Licensed material shall only be used by, or under the supervision of:

A. A pharmacist working or designated as an authorized nuclear pharmacist in accordance with 10 CFR 32.72(b)(2)(i) or (4).

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
09-32781-03MD

Amendment No. 20

Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

B. Authorized Nuclear Pharmacists:

Robert G. Bjurstrom, Pharm.D.

Kaylene Evans, R.Ph.

Nicholas Lanzo, Pharm.D.

Patrick Novak, R.Ph.

David Persinger, R.Ph.

Derek Scott, R.Ph.

Bryan Brittain, Pharm.D.

Jeanine Halverson, R.Ph.

David McLeland, R.Ph.

Brian Osterberg, R.Ph.

Brandon L. Rhoades, Pharm.D.

Deirdre Vaught, R.Ph.

Kerry Eberly, R.Ph.

David Herrmann, R.Ph.

Selina Mirjavadi, Pharm.D.

David Osterberg, R.Ph.

Michael Schroeder, Pharm.D.

12. The Radiation Safety Officer for this license is Robert G. Bjurstrom, Pharm.D.

13. A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.

B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.

D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
09-32781-03MD

Amendment No. 20

Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

- E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.
14. Sealed sources containing licensed material shall not be opened by the licensee, except as specifically authorized.
15. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
16. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash provided:
- A. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated, except for radiation labels on materials that are within containers and that will be managed as biomedical waste after they have been released from the licensee.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
09-32781-03MD

Amendment No. 20

Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

B. A record of each such disposal permitted under this license condition shall be retained for 3 years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

17. The licensee is authorized to retrieve, receive and dispose of radioactive waste from its customers, limited to radiopharmacy-supplied syringes and vials and their contents.
18. This license does not authorize distribution to persons exempt from licensing.
19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.
- A. Letter dated February 26, 2015 (ML15058A688)
 - B. Letter dated May 24, 2017 (ML17150A233)
 - C. Letter dated September 21, 2017 (ML17265A584)
 - D. Letter dated September 28, 2017 (ML17272A866)
 - E. Letter dated November 7, 2017 (ML17313A606)
 - F. Letter dated December 20, 2017 (ML17354A641)
 - G. Letter dated August 7, 2019 (ML19225D279)
 - H. Letter dated October 8, 2019 (ML19282A186)
 - I. Letter dated January 16, 2020 (ML20021A273)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License No.:
09-32781-03MD

Amendment No. 20

Docket or Reference No.:
030-38279 030-30262/24-04206-11MD

J. Letter dated February 8, 2022 (ML22040A267)

K. Letter dated August 15, 2022 (ML22229A091)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: September 15, 2022By: _____
Sara A. Forster
Region III